profit from every $100 of sales.
$0$100
Mineralys Therapeutics
$15.52-1.83% today
-65.0% in 1 year
1-year low $15.241-year high $44.29
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Mineralys Therapeutics sold, what it kept, and what it did with the cash.
Sales went from $0 in 2022 to $0 in 2025, with -$155 million of profit last year.
SalesProfit
Mineralys Therapeutics vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Mineralys Therapeutics | No profit yet | ||
 Vertex Pharmaceuticals | 35.1× · Expensive | ||
 Moderna | No profit yet | ||
 Regeneron Pharmaceuticals | 21.0× · Fair price | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads Mineralys Therapeutics's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 0 | 0 | |
| – | – | – | – | |
| -31 | -85 | -192 | -171 | |
| -31 | -85 | -192 | -171 | |
| -30 | -72 | -178 | -155 | |
| -0.76 | -1.99 | -3.66 | -2.29 | |
| – | – | – | – | |
| – | – | – | – | |
| – | – | – | – |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 114 | 252 | 206 | 662 |
| Cash | 88 | 49 | 114 | 173 |
| Total debt | – | – | – | – |
| Total liabilities | 167 | 10 | 15 | 15 |
| -52 | 241 | 191 | 647 | |
| 39 | 36 | 49 | 68 | |
| – | -27.7% | -79.5% | -20.8% | |
| 57.0% | -29.8% | -93.0% | -23.9% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -29 | -81 | -166 | -142 | |
| – | – | 0 | 0 | |
| -29 | -81 | -166 | -142 | |
| Dividends paid | – | – | – | – |
| 2 | – | – | – | |
| 0 | 5 | 11 | 19 |
Valuation
- –
- –
- –
- 4.1×
- –
- –
- –
- -10.4%
- -11.3%
- 0.0%
Profitability
- 0.0%
- 0.0%
- 0.0%
- 0.0%
- -26.9%
- -1.0%
- -27.9%
- -23.2%
- -26.9%
- –
Growth
- –
- –
- +14.4%
- –
- +91.9%
Financial health
- -0.7×
- 0.00
- 0.0%
- –
- 44.33
- 44.33
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 18%of 953
Bottom 21%of 877
Bottom 11%of 988
What analysts expect
- Average price target
- $46.00
- Range
- $30.00 – $56.00
- 2 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 6, 2026 | -0.47 | -0.51 | +7.8% |
| Mar 12, 2026 | -0.40 | -0.52 | +22.5% |
| Nov 10, 2025 | -0.52 | -0.66 | +21.2% |
| Aug 12, 2025 | -0.66 | -0.78 | +15.4% |
| May 12, 2025 | -0.79 | -1.02 | +22.5% |
| Feb 12, 2025 | -0.98 | -1.00 | +2.0% |
| Nov 11, 2024 | -1.13 | -0.83 | −36.1% |
| Aug 13, 2024 | -0.83 | -0.73 | −13.7% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
23No pass
Benjamin Graham
40No pass
Philip Fisher
34No pass
Peter Lynch
60Pass
Joel Greenblatt
0No pass
Charlie Munger
29No pass
Terry Smith
29No pass
Questions about Mineralys Therapeutics
Is Mineralys Therapeutics a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Mineralys Therapeutics AI analysis
What does Mineralys Therapeutics do?
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It is in Biotechnology.
Does Mineralys Therapeutics pay a dividend?
No. Mineralys Therapeutics does not pay a dividend at the moment.
Is Mineralys Therapeutics stock halal?
Questionable. Mineralys Therapeutics sits in a grey zone: short-term investments may earn interest; type not reported. How we check
How has Mineralys Therapeutics stock done over the past year?
Down 65.0% over the past twelve months, to $15.52. It traded between $15.24 and $44.29 and is 65.0% below its high.
Who are Mineralys Therapeutics's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with Mineralys Therapeutics's.
Prices: daily closes to Nov 10, 2026. Fundamentals: company reports via invest-like data.